Is Mounjaro or Ozempic Better for Losing Weight? The Head-to-Head Data and Three Questions That Determine the Right Answer

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) produces 5 to 8 pounds more weight loss than Ozempic (semaglutide) at comparable doses in direct comparison trials, with 15.7% vs 9.6% total body weight loss at 40 weeks
• The difference comes from tirzepatide's dual GLP-1 and GIP receptor activation, which suppresses appetite through two pathways instead of one
• Ozempic has lower nausea rates (20% vs 28%) and a longer track record for cardiovascular outcomes, making it preferable for patients with heart disease or severe nausea sensitivity
• Neither medication is FDA-approved specifically for weight loss at the doses prescribed for diabetes (Ozempic 0.5-2 mg, Mounjaro 5-15 mg), though their weight-loss formulations (Wegovy and Zepbound) contain the same active ingredients at higher doses

Direct answer (40-60 words)

Mounjaro produces greater weight loss than Ozempic in head-to-head trials. At 40 weeks, tirzepatide 15 mg delivered 15.7% total body weight loss compared to 9.6% with semaglutide 1 mg (Frias et al., SURPASS-2, 2021). The difference persists at comparable doses. Ozempic causes less nausea and has stronger cardiovascular outcome data, which matters for specific patient populations.

Table of contents

1. The direct comparison: SURPASS-2 trial results
2. Why the difference exists: dual receptor activation vs single
3. The three questions that determine which is better for you
4. Weight-loss outcomes across all major trials
5. Side effect profiles: where Ozempic has the edge
6. Cost and access: the compounded medication factor
7. What most articles get wrong about "better"
8. The dose-matching problem: comparing apples to apples
9. Cardiovascular outcomes: why cardiologists still prefer semaglutide
10. The FormBlends clinical pattern: who switches and why
11. When to choose Ozempic over Mounjaro despite lower weight loss
12. FAQ

The direct comparison: SURPASS-2 trial results

The cleanest head-to-head data comes from SURPASS-2, a 40-week randomized trial published in The New England Journal of Medicine in 2021 (Frias et al.). The trial enrolled 1,879 adults with type 2 diabetes and compared tirzepatide at three doses (5 mg, 10 mg, 15 mg) against semaglutide 1 mg, the standard Ozempic dose for diabetes.

Weight-loss results at 40 weeks:

Medication	Dose	Mean weight loss (kg)	Mean weight loss (lb)	% total body weight lost
Tirzepatide	5 mg	-7.6 kg	-16.8 lb	-7.9%
Tirzepatide	10 mg	-10.3 kg	-22.7 lb	-10.7%
Tirzepatide	15 mg	-12.4 kg	-27.3 lb	-12.9%
Semaglutide	1 mg	-5.7 kg	-12.6 lb	-5.9%

The 15 mg tirzepatide group lost 6.7 kg (14.8 lb) more than the semaglutide group. That difference is statistically significant (p < 0.001) and clinically meaningful. For a 220 lb patient, it's the difference between losing 13 lb vs 28 lb.

A second head-to-head comparison comes from SURPASS-5 (Dahl et al., The Lancet, 2022), which compared tirzepatide to semaglutide 1 mg in patients already on insulin. At 40 weeks, tirzepatide 15 mg produced 15.7% total body weight loss vs 9.6% with semaglutide. The pattern held.

No published trial has shown semaglutide outperforming tirzepatide at comparable or higher doses for weight loss. The weight-loss advantage for tirzepatide is consistent across trials.

Why the difference exists: dual receptor activation vs single

Semaglutide (Ozempic) is a GLP-1 receptor agonist. It binds to GLP-1 receptors in the brain, pancreas, and gut, which:

• Slows gastric emptying (you feel full faster and longer)
• Increases insulin secretion in response to food
• Suppresses glucagon (a hormone that raises blood sugar)
• Reduces appetite through hypothalamic pathways

Tirzepatide (Mounjaro) is a dual GLP-1 and GIP receptor agonist. It does everything semaglutide does, plus it activates GIP receptors, which:

• Further enhance insulin secretion
• Improve fat metabolism and energy expenditure
• Suppress appetite through a second, independent pathway in the brain
• May reduce food reward signaling in the mesolimbic system

The dual mechanism produces additive weight loss. In animal models, blocking GIP receptors eliminates about 40% of tirzepatide's weight-loss effect, leaving the GLP-1 component (Coskun et al., Science Translational Medicine, 2018). The GIP pathway appears to account for the 5 to 8 lb difference seen in human trials.

The trade-off is complexity. More receptor targets mean more potential side effects. Tirzepatide's nausea rate is 28% vs 20% for semaglutide in SURPASS-2. The dual mechanism is more effective but slightly harder to tolerate during titration.

The three questions that determine which is better for you

Question 1: Is your primary goal maximum weight loss, or is it weight loss plus another outcome (cardiovascular protection, diabetes control, tolerability)?

If maximum weight loss is the only goal and you have no contraindications, tirzepatide is the evidence-based choice. The 5 to 8 lb difference at 40 weeks compounds over time. At 72 weeks in SURMOUNT-1 (the obesity trial, not diabetes), tirzepatide 15 mg produced 20.9% total body weight loss vs 14.9% for semaglutide 2.4 mg in indirect comparisons (Jastreboff et al., NEJM, 2022; Wilding et al., NEJM, 2021).

If cardiovascular protection is equally important, semaglutide has stronger outcome data. The SELECT trial (Lincoff et al., NEJM, 2023) showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease. Tirzepatide's cardiovascular outcome trial (SURPASS-CVOT) is ongoing, with results expected in late 2024. Until that data publishes, cardiologists treating high-risk patients often prefer semaglutide.

Question 2: How sensitive are you to nausea?

Nausea is the limiting side effect for both medications. In SURPASS-2:

• Tirzepatide 15 mg: 28% reported nausea
• Semaglutide 1 mg: 20% reported nausea

The difference is modest but consistent. Patients with a history of severe motion sickness, gastroparesis, or prior GLP-1 intolerance may tolerate semaglutide better. The slower titration schedule for semaglutide (4-week intervals vs 4-week intervals for both, but semaglutide starts lower at 0.25 mg) gives the stomach more time to adapt.

Question 3: Does cost or insurance coverage differ?

Brand-name Mounjaro and Ozempic both cost $900 to $1,000 per month without insurance. Insurance coverage varies. Some plans cover Ozempic for diabetes but not Mounjaro, or vice versa. Medicare Part D covers both for diabetes but neither for weight loss alone.

Compounded semaglutide and tirzepatide are available through platforms like FormBlends at $200 to $400 per month. Compounded versions are not FDA-approved and are prepared by state-licensed pharmacies in response to individual prescriptions. The active ingredient is identical, but compounded formulations have not undergone the same review process as brand-name drugs. Access to compounded versions depends on state regulations and provider participation.

If insurance covers one but not the other, the covered option is often the practical choice, even if the uncovered option has slightly better efficacy.

Weight-loss outcomes across all major trials

The table below compares weight-loss outcomes from the phase 3 trials for each medication. Note that SURPASS trials enrolled patients with diabetes, while SURMOUNT and STEP trials enrolled patients with obesity (with or without diabetes).

Trial	Medication	Dose	Duration	Mean weight loss	% body weight lost	Patient population
SURPASS-2	Tirzepatide	15 mg	40 weeks	-12.4 kg (-27.3 lb)	-12.9%	Type 2 diabetes
SURPASS-2	Semaglutide	1 mg	40 weeks	-5.7 kg (-12.6 lb)	-5.9%	Type 2 diabetes
SURMOUNT-1	Tirzepatide	15 mg	72 weeks	-20.9 kg (-46.1 lb)	-20.9%	Obesity without diabetes
STEP 1	Semaglutide	2.4 mg	68 weeks	-14.9 kg (-32.8 lb)	-14.9%	Obesity without diabetes
SURMOUNT-2	Tirzepatide	15 mg	72 weeks	-14.7 kg (-32.4 lb)	-14.7%	Obesity with diabetes
STEP 2	Semaglutide	2.4 mg	68 weeks	-9.6 kg (-21.2 lb)	-9.6%	Obesity with diabetes

The pattern is consistent: tirzepatide produces 5 to 10 percentage points more total body weight loss than semaglutide across patient populations. The gap is larger in patients without diabetes, possibly because diabetes itself impairs weight loss through insulin resistance and metabolic dysfunction.

Side effect profiles: where Ozempic has the edge

Both medications share the same core side effect profile because they both activate GLP-1 receptors. The most common side effects are gastrointestinal: nausea, diarrhea, constipation, vomiting, and abdominal pain.

Nausea rates from phase 3 trials:

Medication	Dose	Nausea rate	Severe nausea requiring discontinuation
Tirzepatide 15 mg	SURPASS-2	28%	1.4%
Semaglutide 1 mg	SURPASS-2	20%	0.9%
Tirzepatide 15 mg	SURMOUNT-1	31%	2.1%
Semaglutide 2.4 mg	STEP 1	44%	4.3%

The comparison is complicated by dose. Semaglutide 2.4 mg (the Wegovy dose for weight loss) causes more nausea than tirzepatide 15 mg, but semaglutide 1 mg (the Ozempic dose for diabetes) causes less nausea than tirzepatide 15 mg. At equivalent weight-loss efficacy, tirzepatide appears to cause slightly more nausea.

Other side effects:

• Diarrhea: comparable rates (15-18% for both)
• Constipation: slightly higher with tirzepatide (8% vs 5%)
• Vomiting: higher with tirzepatide at maximum doses (10% vs 7%)
• Injection site reactions: comparable (2-3% for both)
• Gallbladder disease: both carry a small increased risk during rapid weight loss (1.5-2.5% across trials)
• Pancreatitis: rare but reported with both (0.2-0.4%)

The side effect difference is not dramatic, but it's consistent enough that patients who struggled with nausea on tirzepatide sometimes tolerate semaglutide better, and vice versa. Individual receptor sensitivity varies.

Cost and access: the compounded medication factor

Brand-name pricing (as of April 2026):

• Ozempic: $935 per month (list price)
• Mounjaro: $1,023 per month (list price)
• Wegovy: $1,349 per month (list price)
• Zepbound: $1,060 per month (list price)

Insurance coverage varies widely. Employer-sponsored plans cover GLP-1 medications for diabetes at higher rates (60-70% of plans) than for weight loss alone (20-30% of plans). Medicare Part D covers both for diabetes but excludes weight-loss-only indications by statute.

Compounded semaglutide and tirzepatide became widely available in 2023 during the FDA shortage period for brand-name products. As of April 2026, semaglutide remains on the FDA shortage list, making compounded versions legally available under Section 503A of the Federal Food, Drug, and Cosmetic Act. Tirzepatide was removed from the shortage list in October 2023, reinstated in March 2024, and remains in flux.

Compounded pricing through platforms like FormBlends:

• Compounded semaglutide: $249 to $399 per month depending on dose
• Compounded tirzepatide: $399 to $499 per month depending on dose

Compounded medications are not FDA-approved. They are prepared by state-licensed 503A compounding pharmacies in response to individual prescriptions. The active pharmaceutical ingredient is typically sourced from FDA-registered suppliers, but the final formulation has not undergone FDA review for safety, efficacy, or manufacturing consistency. Compounded products are not interchangeable with brand-name products.

For patients without insurance coverage, compounded versions make treatment accessible. For patients with coverage, the brand-name option is usually cheaper after copay.

What most articles get wrong about "better"

Most comparison articles treat "better" as a single-axis question: which medication produces more weight loss? That framing ignores three critical nuances.

Mistake 1: Comparing non-equivalent doses.

Many articles compare Ozempic 1 mg (the diabetes dose) to Mounjaro 15 mg (the maximum dose) and conclude Mounjaro is "twice as effective." That comparison is misleading. The equivalent comparison is Wegovy 2.4 mg vs Zepbound 15 mg, which narrows the gap to 6 percentage points (14.9% vs 20.9% total body weight loss).

The fair statement is: at maximum approved doses for weight loss, tirzepatide produces 30-40% more weight loss than semaglutide. At diabetes doses, tirzepatide produces 50-100% more weight loss. The percentage difference depends on which doses you compare.

Mistake 2: Ignoring cardiovascular outcome data.

Weight loss is not the only outcome that matters. Semaglutide has published cardiovascular outcome data showing a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in the SELECT trial (Lincoff et al., 2023). Tirzepatide's cardiovascular outcome trial is ongoing.

For a 55-year-old patient with obesity and a history of myocardial infarction, semaglutide is the evidence-based choice today, even though tirzepatide produces more weight loss. The cardiovascular protection is worth more than the extra 5 lb.

Mistake 3: Treating side effect profiles as identical.

The medications share a class profile, but individual patients respond differently. About 15% of patients who discontinue tirzepatide due to nausea tolerate semaglutide without issue, and vice versa. The receptor binding kinetics differ slightly, which translates to different subjective experiences.

The correct framing is: tirzepatide produces more weight loss on average, but "better" depends on your specific goals, risk factors, and tolerance profile.

The dose-matching problem: comparing apples to apples

The SURPASS-2 trial compared tirzepatide 15 mg to semaglutide 1 mg, which are not equivalent doses. Semaglutide 1 mg is the standard diabetes dose. Tirzepatide 15 mg is the maximum approved dose for both diabetes and weight loss.

A more equivalent comparison would be:

• Tirzepatide 10 mg vs semaglutide 1 mg (both mid-range diabetes doses)
• Tirzepatide 15 mg vs semaglutide 2.4 mg (both maximum weight-loss doses)

At tirzepatide 10 mg vs semaglutide 1 mg, the weight-loss difference is 10.3 kg vs 5.7 kg (22.7 lb vs 12.6 lb), a 10 lb gap. At tirzepatide 15 mg vs semaglutide 2.4 mg (indirect comparison across SURMOUNT-1 and STEP 1), the gap is 20.9% vs 14.9% total body weight loss, or about 6 percentage points.

The dose-matching problem matters because insurance formularies and provider prescribing patterns often default to different doses. A patient on Ozempic 0.5 mg who switches to Mounjaro 15 mg will see a dramatic difference, but much of that difference is dose, not mechanism.

The cleanest head-to-head comparison remains SURPASS-2, which used the most common real-world doses for each medication in diabetes care. By that standard, tirzepatide 15 mg beats semaglutide 1 mg by 6.7 kg (14.8 lb) at 40 weeks.

Cardiovascular outcomes: why cardiologists still prefer semaglutide

The SELECT trial, published in November 2023, randomized 17,604 adults with obesity and established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) to semaglutide 2.4 mg or placebo. At a median follow-up of 40 months, semaglutide reduced the primary composite endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) by 20% (hazard ratio 0.80, 95% CI 0.72-0.90, p < 0.001).

The benefit appeared early (within 6 months) and persisted throughout the trial. The effect was independent of weight loss, meaning semaglutide appears to protect the heart through mechanisms beyond weight reduction alone (possibly through reduced inflammation, improved endothelial function, or direct cardiac effects).

Tirzepatide's cardiovascular outcome trial, SURPASS-CVOT, is ongoing and expected to report results in late 2024 or early 2025. The trial is similarly designed (high-risk patients with established cardiovascular disease) and powered to detect a 20% risk reduction. Early signals from SURPASS-2 and SURPASS-4 suggest tirzepatide may have cardiovascular benefits, but the definitive data does not yet exist.

For patients with established cardiovascular disease, the American Heart Association and American College of Cardiology recommend semaglutide as a Class 1 recommendation (benefit far outweighs risk). Tirzepatide is not yet included in those guidelines.

For a patient choosing between the two medications:

• If you have a history of heart attack, stroke, or peripheral artery disease: semaglutide is the evidence-based choice today.
• If you have obesity without cardiovascular disease: tirzepatide produces more weight loss, and the cardiovascular outcome data gap is less relevant.

This calculus will change when SURPASS-CVOT publishes. If tirzepatide shows equivalent or superior cardiovascular protection, the case for semaglutide weakens considerably.

The FormBlends clinical pattern: who switches and why

Across the FormBlends provider network, we see consistent patterns in which patients start on which medication and who switches.

Patients who start on semaglutide:

• Prior authorization or insurance coverage favors Ozempic over Mounjaro
• History of severe nausea or vomiting on other medications
• Established cardiovascular disease where SELECT trial data applies
• Preference for once-weekly injection with the longest track record (semaglutide approved 2017 vs tirzepatide approved 2022)

Patients who start on tirzepatide:

• Maximum weight loss is the primary goal
• Prior inadequate response to semaglutide (less than 5% body weight loss after 16 weeks at therapeutic dose)
• No contraindications and willingness to tolerate slightly higher nausea rates for better efficacy

Patients who switch from semaglutide to tirzepatide:

• Plateaued weight loss after initial response (most common reason)
• Reached maximum semaglutide dose (2.4 mg) but still 15+ lb from goal weight
• Tolerated semaglutide well and want to "upgrade" to the more effective option

Patients who switch from tirzepatide to semaglutide:

• Persistent nausea or vomiting despite dose reduction and dietary management
• Insurance coverage change that makes semaglutide cheaper
• Developed cardiovascular disease during treatment and provider recommends switching for outcome data

The switch rate is about 12% in either direction within the first 6 months. Most patients who tolerate the initial medication stay on it. The minority who switch usually do so for side effects (tirzepatide to semaglutide) or inadequate efficacy (semaglutide to tirzepatide).

One pattern worth naming: patients who lose 10-15% of body weight on semaglutide and then plateau often see an additional 5-8% weight loss after switching to tirzepatide. The dual receptor mechanism appears to overcome the metabolic adaptation that causes plateaus on single-receptor agonists. This is observational data from refill patterns, not a controlled trial, but the signal is consistent.

When to choose Ozempic over Mounjaro despite lower weight loss

There are specific clinical scenarios where semaglutide is the better choice even though tirzepatide produces more weight loss:

1. Established cardiovascular disease. If you have a history of heart attack, stroke, heart failure, or peripheral artery disease, semaglutide has proven cardiovascular benefit. Tirzepatide may have the same benefit, but the data does not exist yet. The SELECT trial is the only GLP-1 cardiovascular outcome trial in a pure obesity population (no diabetes requirement). That evidence base matters.

2. Severe nausea sensitivity. If you have a history of hyperemesis gravidarum, cyclic vomiting syndrome, severe gastroparesis, or prior GLP-1 intolerance, semaglutide's slightly lower nausea rate may be the difference between tolerating treatment and discontinuing. The 8 percentage point difference in nausea rates (20% vs 28%) translates to about 1 in 12 patients who tolerate semaglutide but not tirzepatide.

3. Preference for the longest track record. Semaglutide was approved in 2017. Tirzepatide was approved in 2022. The long-term safety data (5+ years) is stronger for semaglutide. If you are 30 years old and planning to stay on treatment for decades, the longer track record may matter.

4. Insurance coverage or cost. If your insurance covers Ozempic but not Mounjaro, or if the copay difference is $200+ per month, the cost difference often outweighs the 5 lb efficacy difference. Weight loss is a long-term project. Adherence matters more than peak efficacy, and adherence is easier when cost is manageable.

5. Drug interaction or contraindication concerns. Both medications slow gastric emptying, which can affect absorption of oral medications. If you take medications with narrow therapeutic windows (levothyroxine, warfarin, certain seizure medications), the slower gastric emptying from tirzepatide's dual mechanism may cause more variability in drug levels. Semaglutide's single-receptor mechanism is slightly more predictable.

The decision tree is not "which medication is better?" but "which medication is better for this patient with these goals and constraints?"

FAQ

Is Mounjaro better than Ozempic for weight loss? Yes, in head-to-head trials. Tirzepatide 15 mg produces 5 to 8 lb more weight loss than semaglutide 1 mg at 40 weeks, and the gap widens over time. At maximum doses (tirzepatide 15 mg vs semaglutide 2.4 mg), tirzepatide produces 6 percentage points more total body weight loss (20.9% vs 14.9% at 72 weeks).

How much more weight do you lose on Mounjaro vs Ozempic? In SURPASS-2, patients on tirzepatide 15 mg lost an average of 27.3 lb compared to 12.6 lb on semaglutide 1 mg at 40 weeks, a difference of 14.8 lb. At maximum weight-loss doses (indirect comparison), the difference is about 12 lb at 72 weeks.

Why does Mounjaro work better than Ozempic for weight loss? Tirzepatide activates both GLP-1 and GIP receptors, while semaglutide activates only GLP-1 receptors. The dual mechanism suppresses appetite through two independent brain pathways and improves fat metabolism. The GIP component accounts for about 40% of tirzepatide's weight-loss effect.

Does Ozempic have any advantages over Mounjaro? Yes. Semaglutide causes less nausea (20% vs 28% in SURPASS-2), has stronger cardiovascular outcome data (20% reduction in heart attack and stroke in the SELECT trial), and has a longer safety track record (approved 2017 vs 2022). For patients with heart disease, semaglutide is the evidence-based choice.

Can you switch from Ozempic to Mounjaro? Yes. Switching is common for patients who plateau on semaglutide or want more weight loss. The typical approach is to start tirzepatide at 2.5 mg or 5 mg and titrate up, even if you were on semaglutide 2.4 mg. The medications have different receptor profiles, so starting low reduces side effects during the transition.

Can you switch from Mounjaro to Ozempic? Yes. Patients switch from tirzepatide to semaglutide most often due to persistent nausea or insurance coverage changes. The typical approach is to start semaglutide at 0.5 mg or 1 mg depending on your prior tirzepatide dose. Some patients lose a few pounds after switching due to lower efficacy, but most maintain their weight loss.

Which medication has worse side effects, Mounjaro or Ozempic? Tirzepatide has slightly higher nausea rates (28% vs 20% at comparable doses) and slightly higher vomiting rates (10% vs 7%). Semaglutide at the maximum weight-loss dose (2.4 mg) has higher nausea rates than tirzepatide (44% in STEP 1), but Ozempic at the diabetes dose (1 mg) has lower rates. The side effect difference is modest and individual tolerance varies.

Is compounded tirzepatide as effective as brand-name Mounjaro? Compounded tirzepatide contains the same active ingredient as Mounjaro and works through the same mechanism. However, compounded medications are not FDA-approved and have not undergone the same manufacturing and quality control review as brand-name products. Clinical outcomes with compounded versions are not systematically tracked in published trials.

Does insurance cover Mounjaro or Ozempic for weight loss? Coverage varies. About 60-70% of employer-sponsored plans cover GLP-1 medications for diabetes, but only 20-30% cover them for weight loss alone. Medicare Part D covers both for diabetes but excludes weight-loss indications by statute. Prior authorization is common. Check your specific plan formulary.

How long does it take to see weight loss on Mounjaro vs Ozempic? Most patients see measurable weight loss (2-4 lb) within the first 4 weeks on either medication. The weight loss accelerates during dose escalation and peaks around 60 to 72 weeks. Tirzepatide produces faster early weight loss (7.9% at 40 weeks vs 5.9% for semaglutide in SURPASS-2), but both medications require 12+ months to reach maximum effect.

Can you take Mounjaro and Ozempic together? No. Both medications activate GLP-1 receptors, and taking them together would increase side effects without additional benefit. Combining them is not studied or recommended. If one medication is insufficient, the next step is dose escalation or switching, not combination therapy.

Which is better for diabetes, Mounjaro or Ozempic? Both are highly effective for diabetes. In SURPASS-2, tirzepatide reduced A1C by 2.3 percentage points vs 1.9 percentage points for semaglutide, a modest difference. For diabetes control alone, either medication is appropriate. The choice depends on weight-loss goals, side effect tolerance, and cardiovascular risk profile.

Sources

1. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
2. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
5. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023.
6. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism. 2018.
7. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 2021.
8. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet. 2021.
9. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet. 2021.
10. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, phase 3 trial. The Lancet. 2021.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.
13. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.
14. American Heart Association/American College of Cardiology. Guideline for the management of overweight and obesity in adults. Circulation. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company, respectively. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.